Introduction
About 30% of children and young people with epilepsies do not respond to the first two appropriate antiepileptic drugs (AEDs), and can be considered to have ''intractable'' or ''difficult to treat'' epilepsies. 1, 2 Clobazam (CLB), Topiramate (TOP) and Lamotrigine (LAM) are antiepileptic drugs with different pharmacological actions, with proven efficacy in treating generalised and partial seizures. 3, 4 However, there are few studies of these drugs in children. 5 CLB is marketed for use in children over 3 years, whilst TOP and LAM are both marketed for children over 2 years with difficult to treat epilepsies. This study reports on the use of CLB, TOP and LAM in 224 separate treatment episodes in 194 paediatric patients with difficult to treat epilepsies over an 8 year period.
Methods
Children under 18 years of age starting treatment with CLB, TOP or LAM from September 2000 to April 2008 were ascertained retrospectively from hospital pharmacy and paediatric neurology databases in a tertiary referral paediatric neurology department. CLB, TOP and LAM were prescribed as ''adjunctive therapy'' for controlling difficult to treat focal or generalised epilepsies by two Consultant paediatric neurologists.
A retrospective chart review using a standard pro forma to capture demographic data, aetiology, epilepsy syndrome, seizure frequency, medication dosage, concomitant AEDs, efficacy and adverse events was recorded at more than 2, 6 and 12 months from starting that AED. Efficacy data was analysed using SPSS 18.0 on an intention to treat basis. As this was not a prospective trial with allocation of treatments, but an observational study of recent local practice, the ''intention to treat'' analysis of perceived efficacy used the complete data set including all patients who had started the AED, including those in whom it had been withdrawn. A few patients were omitted from the perceived efficacy analyses at some time windows if they had not been withdrawn but were not observed during that time window.
A B S T R A C T
Clobazam (CLB), Topiramate (TOP) and Lamotrigine (LAM) are newer second-line antiepileptic drugs (AEDs) used in children. This is a single-centre retrospective observational study of the efficacy, tolerability and retention rate in 224 separate treatment episodes in 194 children, aged 0.1-16.7 years (median 9.4) over an 8 year period. The median age of epilepsy onset was 3.3 years (range 0-15.1). 79% started CLB, TOP or LAM as at least the 3rd AED, with 39% having been withdrawn from at least 2 AEDs. 53% had generalised and 37% idiopathic epilepsies. The maintenance doses for CLB ranged 0.12-3.50 mg/ kg/day (mean 0.7); for TOP 0.45-32.0 mg/kg/day (mean 7.1) and for LAM 1.13-16.0 mg/kg/day (mean 5.6). The study comprised 75 person-treatment years for CLB, 56 for TOP, 124 for LAM. Results: CLB, TOP and LAM were well tolerated with 51%, 37% and 69% remaining on treatment beyond 1 year respectfully. 1 serious adverse event for CLB (inducing seizures) and 2 for LAM (rashes) were reported, and 60%, 47% and 39% had possibly and probably related adverse events for CLB, TOP and LAM respectively. Beyond 12 months seizure improvement (<50% seizure frequency compared to baseline) was reported in 43%, 35% and 44% on CLB, TOP and LAM, including 5% and 8% remaining seizure free on CLB and LAM respectively. Conclusion: Our results demonstrate the efficacy and tolerability of CLB, TOP and LAM in children with difficult to treat epilepsies and a good response in CLB and LAM, and a reasonable response in TOP beyond 12 months.
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Statistical tests included simple mean, median and range, ANOVA for difference in age of starting an AED, Chi-Squared for differences in aetiology and seizure type, and Kaplan-Meier survival plot for time on the AED. This was an observational nonintervention study, registered as a clinical audit by the Nottingham University Hospital's NHS Trust.
Results
224 treatment episodes in 194 children (52% female) were ascertained. 73 treatment episodes for CLB, 60 for TOP, and 91 for LAM. 29 patients had been on of two of the AEDs and 1 patient on CLB, TOP and LAM during the study period. There were no differences in their use with respect to gender.
Patients starting each drug had similar age ranges: 0.5-16.7 years (median 7.6) for CLB; 0.3-16.2 years (median 9.9) for TOP; and 1.1-16.2 years (median 10.6) for LAM. However, the age of starting CLB was younger compared to LAM following ANOVA statistical analysis, with Bonferroni correction applied to account for Type 1 error (p = 0.015, 95% CI [À3.91 to À0.32 years]). There was no difference in mean age of starting TOP, compared to LAM and CLB.
The population had mostly early onset of seizures, with a median age of onset of 3 years 3 months (range 0-15 years). CLB, TOP and LAM were used in epilepsies with a variety of aetiologies and locations of epileptic seizure origin and spread. TOP and LAM were used slightly more in idiopathic than symptomatic epilepsies, whilst CLB was used slightly more in symptomatic epilepsies. However these differences were not statistically significant. CLB and TOP were used in similar numbers for generalised and focal epilepsies, with LAM being used slightly more in generalised epilepsies, however this trend was also not statistically significant. 37% of cases had idiopathic, and 53% generalised epilepsies.
Brain imaging (MRI) and electroencephalography (EEG) results were retrieved in 88% and 70% of cases respectfully. In those patients whose MRI reports were available, MRI was abnormal in 52% (29/56) of patients on CLB; 50% (18/36) of patients on TOP; and in 31% (20/64) of patients on LAM. Of EEG reports available, 75% (54/72) were abnormal for patients on CLB, 65% (39/60) for patients on TOP and 77% (51/66) for patients on LAM.
The intractable nature of this study population's epilepsies is demonstrated by the number of previously withdrawn (Table 1) and concomitant AEDs (Table 2) .
No patients were on CLB as a first line treatment, 6/73 had either 1 previously withdrawn or 1 concomitant AED, with 67/73 receiving CLB as the 3rd to 10th choice of AED. No patients were on TOP as the 1st choice of treatment, with 10/60 on TOP having either 1 previously withdrawn or 1 concomitant AED, with 50/60 receiving TOP as the 3rd to 6th choice of AED. 4/91 patients had received LAM as the 1st choice, 26/91 patients on LAM had either 1 previously withdrawn or 1 concomitant AED, and 61/91 were receiving LAM as the 3rd to 6th choice of AED.
This study comprised 74.5 person-treatment-years for CLB; 56.1 for TOP; and 124.4 for LAM. Mean maximum dosage was 0.7 mg/kg/day (range 0.12-3.50) for CLB; 7.1 mg/kg/day (range 0.45-32.0) for TOP; and 5.6 mg/kg/day (range 1.13-16.0) for LAM.
2 patients on CLB; 3 on TOP; and 1 on LAM achieved monotherapy. Of these patients, 1 on each of CLB, TOP and LAM had Idiopathic Generalised Epilepsies, 1 patient on CLB had Symptomatic Focal Epilepsy, and 2 on TOP had Symptomatic Generalised Epilepsies. Both CLB patients and the patient on LAM had a considerable improvement in seizure frequency by the last follow up. 2 of the 3 patients on TOP had a significant improvement with the other 1 demonstrating a lack of efficacy by the last follow up. The majority of these patients had at least 2 previous AEDs (range 0-4).
Possibly and probably related adverse events were reported in 60% on CLB; 47% on TOP; and 39% on LAM. The most frequent adverse events involved excessive sleepiness with 27% of all CLB patients reporting this, behavioural problems and excessive weight loss on TOP with 15% and 12% respectively reporting these. Sleeping problems (difficulties getting to sleep) followed by rash were the most common complaints with 12% and 10% of LAM patients respectively reporting these. Table 3 shows the different reported adverse events for each AED.
Most adverse events appeared within the first 3 months of treatment. The adverse events seen were often at the lower-end of the recommended dosage ranges. Whilst most adverse events were mild and predictable from the pharmacology, 1 serious CLB and 2 serious LAM reactions occurred, resulting in hospitalisation. The chart note suggested that CLB had induced an increase in seizures. The 2 LAM patients that had severe rashes that resulted in hospitalisation were on 0.8 mg/kg/day and 1.5 mg/kg/day. No fatalities occurred as a result of treatment. Most adverse events resolved without requiring withdrawal of medication, however 8/ 73 (11%) on CLB; 9/60 (15%) on TOP; and 11/91 (12%) LAM patients were withdrawn from their medication as a consequence of adverse reactions.
31/73 (42%) children withdrew from CLB: 8 because of adverse events, 19 lack of efficacy, 1 poor concordance (adherence), and 3 being seizure free. 29/60 (48%) were withdrawn from TOP: 9 because of adverse events, and 20 due to lack of efficacy. 35/91 (38%) were withdrawn from LAM: 11 because of adverse events, 19 due to lack of efficacy, 2 due to poor concordance, and 3 being seizure free (Table 4) . Data was analysed on 224 treatment episodes at 2 < 6 months, 177 at 6 < 12 months and 136 at over 12 months follow up. 43/73 were still being followed on CLB; 29/60 on TOP; and 64/91 on LAM, at last observation beyond 12 months. 88 children were not followed up beyond 12 months due to missing data, due to not attending clinic frequently enough or missing appointments, transfer to adult services, or withdrawal from CLB, TOP, or LAM prior to 12 months.
Retention rates beyond 12 months, of all patients commenced on treatment, and assuming those lost to follow up had come off the AED, were for CLB 51% (37/73), for TOP 37% (22/60), and for LAM 69% (63/91) (Fig. 1) . The differences in time spent on each drug were not significant.
Seizure response rates of greater than 50% reduction were highest at 2 months for TOP and LAM with 37% (22/60) and 47% (43/91) improved respectfully, and seizure response was highest at 6 months for CLB with 49% (36/73) improved. Seizure improvement beyond 12 months for CLB was 25% (18/73), and 33% (30/91) for those on LAM. Additionally, 4% (3/73) on CLB and 3% (3/91) started on LAM demonstrated seizure freedom. TOP did not perform as well, with 17% (10/60) demonstrating an improvement beyond 12 months, without any patients achieving seizure freedom. Patients achieving an initially good response tended to maintain a reduction in seizure frequency, even with TOP.
Discussion
The three AEDs in this retrospective observational study have all previously demonstrated their efficacy in trials. [6] [7] [8] CLB is a 1,5 benzodiazepine, selective for the v-2 subunit of the GABA-A inhibitory receptor, where it causes agonist effects and Cl À influx. 9 TOP is considered to have many potential mechanisms such as modifying Na + and Ca 2+ potentials, moderating Cl À influx via GABA receptors and inhibition of glutamate receptors. 10 LAM is unrelated to other available AEDs and probably acts by voltagedependent blockage of sodium channels, and/or inhibiting excitatory amino acid release, such as glutamate. 11 Each drug has been shown to be effective and tolerated in children with focal and generalised epilepsies. [12] [13] [14] However, there is a lack of studies that demonstrate efficacy in unselected children with difficult to treat epilepsies. This study adds to the existing literature by comparing the effects of CLB, TOP and LAM in a defined paediatric cohort, and evaluates the effects of the drugs on seizure frequency and safety profile in the reality of clinical practice. This study is important, since children with intractable or difficult to treat epilepsies often have co-morbidities such as developmental delay, behavioural problems and motor or speech impairments, and typically take a number of other medicines, including changing doses of other AEDs.
Whilst 60% of those on CLB, 47% on TOP and 39% on LAM reported adverse events attributable to the medication, many of these events were predictable, such as the 27% of all patients on CLB feeling more sleepy, or the 12% with loss of weight and appetite on TOP. Many of these problems whilst related to the medication, were tolerated by the children and caregivers, and were deemed to be mild enough not to withdraw treatment. Only 11% of CLB, 15% of TOP and 12% of LAM patients starting treatment were withdrawn as a consequence of adverse effects.
This study is limited due to the retrospective data collection, since it is possible some adverse events could be due to concomitant AEDs or other medication. Additionally, since many children had behavioural and learning problems initially, it is difficult to attribute these to the medication per se, since this study was not geared to assess changes in patient characteristics. It is nonetheless important that cognitive, social and developmental effects encountered by the patient are recorded, whether these changes are multifactorial in cause or not.
One serious adverse event was attributed to CLB: increasing seizures; and 2 serious events occurred with LAM: rashes that required hospitalisation, however, the rate of rash seen in this paediatric cohort is as expected, with values in the literature suggesting 5-10% of child patients may experience a rash associated with LAM, particularly children aged under 13 years. 15 Both children experiencing a rash were aged 9 and 10, and had been exposed to a very low dose of LAM (1.5 and 0.8 mg/kg/day respectively). Both reactions occurred soon after commencing treatment, after 34 and 46 days respectively.
The strength of this study is the reality of drug use in the practical clinical setting where a variety of confounding factors can influence treatment as opposed to the strict control of variables in the randomised control trial setting. Assessing the impact on patient behaviour, mood and cognition would require a prospective study that records objectively changes in behaviour and cognition before attributing change in behaviour and cognition to use of CLB, TOP or LAM.
Retention was favourable for both CLB and LAM with 51% (37/ 73) and 69% (63/91) respectively, and 37% (22/60) on TOP remaining on treatment 12 months and more since commencing treatment.
The results of those continuing treatment throughout the three observation periods of 2 < 6, 6 < 12 and 12+ months since commencing treatment are the most useful measure of how each drug performed in terms of efficacy and tolerability in the [ ( ) T D $ F I G ] paediatric cohort. The results of this study support the findings of tolerability and efficacy of similar studies of children with intractable epilepsies. [16] [17] [18] Seizure freedom was achieved in 3/73 (4%) on CLB and 3/91 (3%) on LAM after 12 months of treatment, whilst a further 33% (30/91) and 25% (18/73) on LAM and CLB had a significant reduction (<50% fewer seizures compared to baseline) in seizure frequency by the same time. 17% (10/60) on TOP had fewer seizures after 12 months of being on treatment, with no patients on TOP achieving seizure freedom.
These results demonstrate that a substantial number of young patients with intractable epilepsies will benefit from treatment with CLB or LAM, and a reasonable number may benefit from treatment with TOP, whatever the epilepsy category.
The methods used in this study are comparable to those used in other studies of newer AEDs like Levetiracetam, Zonisamide, and Gabapentin [19] [20] [21] so the results may be compared to the performance of those drugs in intractable epilepsies in the paediatric population.
Our study confirms the efficacy, tolerability and safety profile of CLB, TOP and LAM in a paediatric cohort with intractable epilepsies. Multicentre prospective studies would be required to demonstrate the longer-term efficacy and the impact these drugs have on the behavioural and cognitive functions of children.
Comparison with other AEDs could be also be made using this method.
Conclusions
This study confirms the efficacy and safety profile of CLB, TOP and LAM in young people with intractable epilepsies
